




21




OP-1088




OP-1074*HCl



OP-1086




OP-1084



OP-1085

where R^{10} is $-C(=O)R^{C1}$, $-C(=O)OR^{C1}$, $-C(=O)SR^{C1}$, $-C(=O)N(R^{C1})_2$; or polyethylene glycol, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; $-S(=O)_2R^{C1}$, $-S(=O)_2OR^{C1}$, $-S(=O)R^{C1}$, $-S(=O)OR^{C1}$, $-P(=O)_2R^{C1}$, $-P(=O)_2OR^{C1}$, $-P(=O)(OR^{C1})_2$, $-P(=O)(R^{C1})_2$, $-P(R^{C1})(OR^{C1})$ or OPO_3H_3 ; or oxygen attached to an oxygen protecting group (to produce OH on administration), sulfur attached to a sulfur protecting group (to produce SH or a disulfide on administration), or nitrogen attached to a nitrogen protecting group (to produce -NH- on administration); and R^{C1} can be independently selected from hydrogen, polyethylene glycol, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R^{C1} groups are joined to form an substituted or unsubstituted heterocyclic ring, or its pharmaceutically acceptable salt.

10. A compound of the structure:








wherein R_1 and R_2 are independently H, halogen, natural or non-naturally occurring amino acid (bound through either the $OC(O)-$ or $C(O)O-$ (an ester) or the amino (through either $-C(O)-N-$ or $-N-C(O)-$ (an amide linkage)), R^{10} , $-OR^{10}$, or $-SR^{10}$ where R^{10} is $-C(=O)R^{C1}$, $-C(=O)OR^{C1}$, $-C(=O)SR^{C1}$, $-C(=O)N(R^{C1})_2$; or polyethylene glycol, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or


unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; $-S(=O)_2R^{C1}$, $-S(=O)_2OR^{C1}$, $-S(=O)R^{C1}$, $-S(=O)OR^{C1}$, $-P(=O)_2R^{C1}$, $-P(=O)_2OR^{C1}$, $-P(=O)(OR^{C1})_2$, $-P(=O)(R^{C1})_2$, $-P(R^{C1})(OR^{C1})$ or OPO_3H_3 ; or oxygen attached to an oxygen protecting group (to produce OH on administration), sulfur attached to a sulfur protecting group (to produce SH or a disulfide on administration), or nitrogen attached to a nitrogen protecting group (to produce -NH- on administration); and R^{C1} can be independently selected from hydrogen, polyethylene glycol, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R^{C1} groups are joined to form an substituted or unsubstituted heterocyclic ring,

or its pharmaceutically acceptable salt.





11. The compound of claim 9, wherein R_1 and R_2 are $-OR^{10}$.
12. The compound of claim 10, wherein R_1 and R_2 are $-OR^{10}$.
13. The compound of claim 9, wherein R_1 is hydrogen.
14. The compound of claim 10, wherein R_1 is hydrogen.
15. The compound of claim 11, wherein $-OR^{10}$ is $-O-C(=O)$ -substituted or unsubstituted alkyl.
16. The compound of claim 12, wherein $-OR^{10}$ is $-O-C(=O)$ -substituted or unsubstituted alkyl.
17. The compound of claim 11, wherein $-OR^{10}$ is $-O-C(=O)$ -substituted or unsubstituted aryl.
18. The compound of claim 12, wherein $-OR^{10}$ is $-O-C(=O)$ -substituted or unsubstituted aryl.
19. The compound of claim 11, wherein $-OR^{10}$ is OPO_3H_3 .
20. The compound of claim 12, wherein $-OR^{10}$ is OPO_3H_3 .
21. The compound of claim 9, selected from the group consisting of:




, and




22. The compound of claim 10, selected from the group consisting of:




21




OP-1088




OP-1074*HCl



OP-1086



OP-1084




OP-1085

where R^{10} is $-C(=O)R^{C1}$, $-C(=O)OR^{C1}$, $-C(=O)SR^{C1}$, $-C(=O)N(R^{C1})_2$; or polyethylene glycol, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; $-S(=O)_2R^{C1}$, $-S(=O)_2OR^{C1}$, $-S(=O)R^{C1}$, $-S(=O)OR^{C1}$, $-P(=O)_2R^{C1}$, $-P(=O)_2OR^{C1}$, $-P(=O)(OR^{C1})_2$, $-P(=O)(R^{C1})_2$, $-P(R^{C1})(OR^{C1})$ or PO_3H_2 ; or oxygen attached to an oxygen protecting group (to produce OH on administration), sulfur attached to a sulfur protecting group (to produce SH or a disulfide on administration), or nitrogen attached to a nitrogen protecting group (to produce -NH- on administration); and R^{C1} can be independently selected from hydrogen, polyethylene glycol, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R^{C1} groups are joined to form an substituted or unsubstituted heterocyclic ring,

or its pharmaceutically acceptable salt.

10. A compound of the structure:








wherein R_1 and R_2 are independently H, halogen, natural or non-naturally occurring amino acid (bound through either the $OC(O)-$ or $C(O)O-$ (an ester) or the amino (through either $-C(O)-N-$ or $-N-C(O)-$ (an amide linkage)), R^{10} , $-OR^{10}$, or $-SR^{10}$


where R^{10} is $-C(=O)R^{C1}$, $-C(=O)OR^{C1}$, $-C(=O)SR^{C1}$, $-C(=O)N(R^{C1})_2$; or polyethylene glycol, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or

unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; $-S(=O)_2R^{C1}$, $-S(=O)_2OR^{C1}$, $-S(=O)R^{C1}$, $-S(=O)OR^{C1}$, $-P(=O)_2R^{C1}$, $-P(=O)_2OR^{C1}$, $-P(=O)(OR^{C1})_2$, $-P(=O)(R^{C1})_2$, $-P(R^{C1})(OR^{C1})$ or PO_3H_2 ; or oxygen attached to an oxygen protecting group (to produce OH on administration), sulfur attached to a sulfur protecting group (to produce SH or a disulfide on administration), or nitrogen attached to a nitrogen protecting group (to produce -NH- on administration); and R^{C1} can be independently selected from hydrogen, polyethylene glycol, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R^{C1} groups are joined to form an substituted or unsubstituted heterocyclic ring,

or its pharmaceutically acceptable salt.

11. The compound of claim 9, wherein R_1 and R_2 are $-OR^{10}$.
12. The compound of claim 10, wherein R_1 and R_2 are $-OR^{10}$.
13. The compound of claim 9, wherein R_1 is hydrogen.
14. The compound of claim 10, wherein R_1 is hydrogen.
15. The compound of claim 11, wherein $-OR^{10}$ is $-O-C(=O)$ -substituted or unsubstituted alkyl.
16. The compound of claim 12, wherein $-OR^{10}$ is $-O-C(=O)$ -substituted or unsubstituted alkyl.
17. The compound of claim 11, wherein $-OR^{10}$ is $-O-C(=O)$ -substituted or unsubstituted aryl.
18. The compound of claim 12, wherein $-OR^{10}$ is $-O-C(=O)$ -substituted or unsubstituted aryl.
19. The compound of claim 11, wherein $-OR^{10}$ is OPO_3H_2 .
20. The compound of claim 12, wherein $-OR^{10}$ is OPO_3H_2 .
21. The compound of claim 9, selected from the group consisting of:





22. The compound of claim 10, selected from the group consisting of:

